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Abstract
The purpose of this integrative review was to assess the research on topical emollients to prevent atopic
dermatitis (AD) also known as eczema, in infants at high risk for this condition. Atopic dermatitis is a common
chronic inflammatory skin disorder. Skin barrier dysfunction plays a prominent role in its development. Topical
emollients have been hypothesized to enhance the skin barrier and prevent AD.

Methods:

Searches were conducted in September 2021 in PubMed, CINAHL, Cochrane Library, and Web of Science using
key word search terms dermatitis, atopic, emollients, petrolatum, and infant, newborn. Inclusion criteria were
articles written in English published between 2010 and 2021 that tested emollients in high-risk infants and
measured the development of AD.

Results:

Eight primary research articles were included. Six studies were limited by small sample sizes, short-term
application of emollients, and short-term follow-up. These studies generated inconclusive results. Two large
randomized controlled trials (RCTs) with a combined sample of 3,791 infants found no evidence that early,
regular use of emollients prevents AD among high-risk infants.

Clinical Implications:

Findings from two high-quality RCTs indicate that clinicians should not recommend use of emollients to prevent
AD. Clinicians may provide evidence-based recommendations for infant skin care, including bathe with water or
a combination of water and liquid cleanser formulated for infants, and avoid soaps. Products applied to skin
should be free of scent and contact allergens. Petroleum jelly or mineral oil is appropriate to moisturize infants'
skin as needed.

Atopic dermatitis is heritable, and infants are considered at high risk for atopic dermatitis if they have a firstdegree relative with a current, or historical, provider- diagnosed atopic dermatitis, asthma, or allergic rhinitis.
Atopic dermatitis (AD), also known as eczema, is a chronic, inflammatory skin disorder that usually begins in
early childhood, typically at ages 3 to 6 months (Langan et al., 2020). Approximately 25% of children will be
diagnosed with AD (American Academy of Dermatology Association, 2021). Eczema is the broader term and
refers to chronic inflammatory skin conditions with eruptions of scaly papules and plaques. Atopic refers to a
dermatitis caused by a hypersensitivity allergy reaction that occurs in a part of the body not in contact with the
allergen. Many, but not all persons, with eczema have IgE-mediated allergic sensitization. Eczema and AD are
commonly used synonymously in clinical practice and in publications (Langan et al.). Signs and symptoms of AD

include varying degrees of elevated IgE levels, skin lesions, dry skin, and pruritis. The skin changes of AD may
present as erythematous papulovesicular plaque lesions, dry scaly hyperpigmented plaques, and areas of
lichenification (Johnson et al., 2021). Some children will experience an early self-resolving condition, whereas
others develop chronicity. Chronic AD may be a pattern of relapsing-remitting inflammation, chronic persistent
dermatitis, or extended periods of remission followed by recurrence (Langan et al.). In estimates of prevalence
of severity of AD, 67% of cases are mild, 26% are moderate, and 7% severe (Kent & Clark, 2018).
Atopic dermatitis can have detrimental effects on the lives of children and their families including social,
academic, and occupational impacts and decreased quality of life (Drucker et al., 2017). Children affected by AD
report a negative effect resulting from burdens of treatments, sleep deprivation from skin irritation, activity
restrictions due to trigger avoidance, and psychologically distressing stigmatizing experiences due to visible
rashes (Tollefson et al., 2014). Caregivers of children with AD report reduction in quality of life. In one study,
97% of caregivers reported decreased quality of life (Al Shobaili, 2010). Reduction in quality of life was
significantly correlated to increasing severity of disease. Caregivers' and families' quality of life is affected by
burdens of caregiving, lack of sleep, feelings of hopelessness and guilt, and financial burdens. In the United
States, the annual estimated costs related to AD range from $364 million to $3.8 billion (Xu et al., 2017). For
families, out-of-pocket costs average $274 per month excluding provider office visits (Filanovsky et al., 2016).
The specific cause of AD is unclear but is associated with genetic and immunologic factors that influence
epidermal barrier function (Johnson et al., 2021). The strongest genetic link to AD is mutations in the gene
encoding for filaggrin (FLG), which is a protein important to creating the skin barrier (Tollefson et al., 2014).
Infants with a first-degree relative with a current, or historical, provider-diagnosed AD, asthma, or allergic
rhinitis are considered at high risk for development of AD (Chalmers et al., 2017). It is hypothesized that a
disrupted skin barrier allows allergens and irritants to penetrate the stratum corneum leading the keratinocytes
and dendritic cells to initiate an inflammatory response with IgE formation and initiation of AD. Disruptions in
the skin barrier can result from scratching, and skin dryness due to the environment, through applied skin
products, or due to filaggrin mutation (Simpson et al., 2014). In infants, immaturity of the stratum corneum
increases their risk for skin barrier dysfunction and risk for development of AD (Telofski et al., 2012).
During the first 12 to 24 months of life, infants' skin is thinner, dryer, and more alkaline than adult skin (Cooke et
al., 2016; Horimukai et al., 2014; Telofski et al., 2012). Infants have low concentration of ceramides in their
stratum corneum at birth. Ceramides are lipid molecules that help the skin retain moisture. As the concentration
of ceramides increase in the weeks following birth, the barrier function of the skin improves (Lowe, Leung, et al.,
2018). Infants' skin is slightly alkaline at birth (pH range 6.3 to 7.5), which increases the activity of protease
enzyme that breaks down connective parts of the stratum corneum (Cooke et al.). Over the first weeks of life,
sebum secretion, lactic acid in sweat, amino acids, and the generation of intracellular lipids cause the skin to
transition to an acidic pH of 4.0 to 6.7, which is essential for epidermal barrier maturation and the repair process
(Telofski et al.).
In the last decade, researchers have concentrated on the prominent role of skin barrier dysfunction in the
development of AD, which has driven research toward strategies for primary prevention. One area of study has
been topical emollients starting shortly after birth to enhance the barrier function of the stratum corneum to
prevent AD (McClanahan et al., 2019). Emollients are lipid substances that moisten and soften skin (Lowe,
Leung, et al., 2018). The lipids are transported through the cell membrane of the keratinocytes and metabolized
within the cell to create a more functional protective epidermal barrier and increased capacity to trap water and
improve hydration of the skin (Chalmers et al., 2017; Simpson et al., 2010; Telofski et al., 2012). The purpose of
this integrative review was to assess the research on the regular application of emollients to the skin to prevent
the development of AD in infants at high risk.

Search Strategy
Working with a medical librarian who established the search strategy, literature searches were conducted in the
following electronic databases: PubMed, CINAHL (Cumulative Index to Nursing and Allied Health Literature),
Cochrane Library, and Web of Science. The results were limited to English language only and published between
2010 through 2021. There was no limit on the type of publication. The search was conducted in September
2021. The search strategy was first established in PubMed using a combination of MeSH (medical subject
headings; database-controlled vocabulary) and keywords. The MeSH headings were searched along with the
keywords. Specific MeSH terminology included “Dermatitis, Atopic”, emollients, petrolatum, and “Infant,
Newborn.” From there, the other database search strategies were developed, and searches were conducted.
(See Table 1 supplemental digital content for list of search strategies at https://links.lww.com/MCN/A74.) With
each database search, database-controlled vocabulary was searched in combination with keywords. The search
is depicted in Figure 1. The initial search yielded 1,138 articles and 678 duplicates were removed. Two
researchers worked together to scan 460 articles for inclusion criteria. Inclusion criteria included primary
research studies that tested application of topical emollients early in life to prevent AD among infants at high
risk for AD. High risk for AD was determined by positive family history of a first-degree relative with AD, allergic
rhinitis, or asthma. The patient-oriented outcome of interest was prevention of the development of AD. Thirtyseven articles were reviewed. Of these, 1 was not retrieved and 28 did not meet inclusion criteria. Eight primary
research articles were included in this integrative review.

FIGURE 1.: PRISMA DIAGRAM

Evaluation of Evidence
The Strength of Recommendation Taxonomy (SORT) criteria were used to appraise the level of evidence of the
individual studies included in this review and of the group of these studies together. Level of evidence is based
on quality, quantity, and consistency of patient-oriented outcomes (Ebell et al., 2004).
Patient-oriented evidence measures outcomes that matter to patients such as morbidity, mortality, symptom
improvement, cost reduction, or quality of life (Ebell et al., 2004). Level of evidence of individual studies was
rated on a scale of 1 to 3 with 1 being the highest. Groups of studies are referred to as bodies of evidence. The
strength of recommendation for the body evidence was rated A, B, or C based on quality of studies and

consistency of patient-oriented evidence across the group, with level A being a strong recommendation and
level C a weak recommendation (Ebell et al.).

Literature Review
Four studies reported inconclusive results on emollient use and prevention of AD among infants at risk for AD
(Lowe, Su, et al., 2018; McClanahan et al., 2019; Simpson et al., 2010; Thitthiwong & Koopitakkajorn, 2019). Two
studies reported significant prevention of AD (Horimukai et al., 2014; Simpson et al., 2014) and three studies
reported no evidence that daily emollient use prevented AD (Chalmers et al., 2020; Skjerven et al., 2020). There
were no serious adverse effects reported in the studies included in this review. One randomized controlled trial
(RCT) revealed small increases in skin infections among infants using daily topical emollients (intervention group;
Chalmers et al.). Summary of included studies is in Table 2.
TABLE 2. - SUMMARY OF STUDIES (N = 8) TESTING USE OF EMOLLIENTS IN INFANTS TO PREVENT ATOPIC
DERMATITIS
First Author,
Location
Age,
Intervention vs.
Limitations
Results
Year, Level of
Design
Sample
Control
Evidence
Size
Chalmers et al.
U.K. (United Newborn
Daily application
Small amount of
At 2 years of life,
(2020) Level 1
Kingdom)
term
of petroleumemollient use in
daily emollient
RCT
infants N = based emollient
control group
during the first
1,394
from 3 weeks of
year of life did not
life to 12 months
prevent AD in
plus standard
high-risk children.
skin-care advice
vs. standard skincare advice only.
Horimukai et al. Japan RCT
Newborn
Daily application
Small sample size;
Treatment led to
(2014) Level 2
term
of emulsion-type
follow-up ended at 48% reduction in
infants N = moisturizer from
8 months at end of risk of
118
first week of life
study
development of
to 8 months vs.
AD (hazard ratio,
use of petroleum
0.48; 95% CI, 0.27jelly 2 days per
0.86).
week.
Lowe, Su, et al.
Australia
Newborn
Twice daily
Small sample size;
Intention to treat
(2018) Level 2
Pilot RCT
term
application of
39% of control
analysis showed
infants N = ceramidegroup and 17% of
no significant
74
dominant
intervention
effect of routine
emollient from
reported use of
barrier lipid
first 3 weeks of
OTC emollients > 3
replacement in
life to 6 months
days per week
early life on AD.
vs. usual care.
McClanahan et
Oregon,
Newborn
Daily application
Study was under
Infants in
al. (2019) Level
United
term
of ceramide and
enrolled and did
intervention group
2
States (U.S.) infants N = amino acid
not reach target
had lower
RCT
100
emollient from
enrollment;
incidence of
first 3 weeks of
adherence to daily
diagnosis of AD at
life to 24 months emollient use
12 months and 2
vs. usual care.
dropped at each
years; however,

assessment point;
45% of control
group had regular
use of OTC
emollient.
Small sample size,
no control group

Simpson et al.
(2010) Level 2

U.S. Openlabel
prospective
study

Newborn
term
infants N =
22

Daily application
of petrolatumbased cream
beginning in first
week of life to
follow-up 3-24
months.

Simpson et al.
(2014) Level 2

U.S. & U.K.
Pilot RCT

Newborn
term
infants N =
124

Daily application
of emollient from
first 3 weeks of
life to 6 months
vs. no emollient.

Small sample size;
follow-up ended at
6 months at end of
intervention.

Skjerven et al.
(2020) Level 1

Norway &
Sweden RCT

Newborn
term
infants N =
2,397

Low protocol
adherence of 27%
in the skin
emollient group

Thitthiwong &
Koopitakkajorn
(2019) Level 2

Bangkok
RCT

Newborn
Infants N =
52

Baths with
emulsified oil and
cream to face 4
days per week
from 2 weeks of
life to 8 months
vs. usual care.
Daily application
of petrolatumbased emollient
vs. usual care
from first 10
weeks of life to 9
months.

the differences
were not
statistically
significant.
15% of infants in
study developed
AD compared with
expected risk of
30%-50% of
developing AD
among high-risk
infants.
Relative risk
reduction of 50%
for development
of AD in treatment
group (relative
risk, 0.50; 95% CI,
0.28-0.9; p = .017).
Early skin
emollients did not
reduce
development of
AD at age 12
months.

Small sample size;
did not reach target
enrollment; shortterm use and
follow-up

At 9 months, none
of the infants in
the treatment
group developed
AD compared with
4 (14.8%) in the
control group (p =
0.045).
Note. RCT = randomized controlled trials; OTC = over-the-counter; AD = atopic dermatitis; CI = confidence
interval.

Inconclusive Evidence for Emollients to Prevent Atopic Dermatitis
The primary pilot study on this topic (Simpson et al., 2010) began the investigation into the use of emollients to
prevent AD. This open-label prospective study tested daily topical Cetaphil cream to prevent AD among 22 highrisk infants (Simpson et al., 2010). The intervention was started in the first 7 days of life. At 24 months follow-up,
15% (N = 3) of infants in this study had developed AD (Simpson et al., 2010). The researchers compared their
results to the relative risk of 30% to 50% that high-risk infants have to develop AD. They reported that their
results were inconclusive but promising that emollients might prevent AD in high-risk infants (Simpson et al.,
2010).

Lowe, Su, et al. (2018) conducted a pilot RCT with 74 infants at high risk for AD. The treatment group used a
specially formulated emollient twice daily from the first 3 weeks of life to 6 months. There were fewer infants
diagnosed with AD at the 12-month follow-up (5% in treatment group vs. 15% in control group); however, an
intention to treat analysis found that this was not a statically significant reduction (Lowe, Su, et al., 2018).
Most recently, an RCT by McClanahan et al. (2019) included 100 infants at high risk for AD. In this study, the
intervention group used moisturizer daily to all body surfaces excluding the scalp and diaper area beginning
within the first 3 weeks of life. Cumulative incidence of AD at 12 months was less, with 13% of the intervention
group and 25% of the control group developing AD (McClanahan et al., 2019). However, this was an
underpowered study that lacked statistical significance due to underenrollment and a higher-than-expected
dropout rate (McClanahan et al.). There were no significant differences in incidence of AD between the
intervention and control groups.
Thitthiwong and Koopitakkajorn (2019) conducted an RCT with 53 high-risk infants. They tested a hospitalformulated petroleum-based emollient compared with usual care. Beginning within the first 10 weeks of life, the
emollient was applied all over the body once per day within 3 to 5 minutes after bathing and patting infant dry.
At the 9-month follow-up, four infants in the control group developed AD compared with zero infants in the
intervention group. This difference was significant at the p = .045; however, the authors recommended caution
with interpreting these results due to the small sample size.

Evidence that Emollients Prevent Atopic Dermatitis
Horimukai et al. (2014) conducted an RCT that included 118 infants at high risk for AD. The treatment group
used daily application of an emulsion-type emollient starting at the first week of life to 8 months versus use of
petroleum jelly in the control group. Researchers reported a significant 32% reduction in diagnosis of AD after
32 weeks among the treatment group in comparison to the control group (hazard ratio, 0.48; 95% CI, 0.27-0.86).
A second study by Simpson et al. (2014) included 124 infants at high risk for AD. The treatment group received a
daily body application of emollient at age 6 months beginning within the first 3 weeks of life (Simpson et al.,
2014). Parents in the control group were asked to use no emollients. The treatment and control groups were
given an information booklet on infant skin care that reflected current guidelines. Infants in the treatment group
had a 50% relative risk reduction in AD at 6 months of age in comparison with the control group (relative risk,
0.50; 95% CI, 0.28-0.9; p = .017; Simpson et al., 2014).

Evidence that Emollients Do Not Prevent Atopic Dermatitis
Chalmers et al. (2020) performed a multicenter, pragmatic, parallel-group RCT that included 1,394 infants. The
intervention group received a daily application of petroleum-based emollient beginning within the first 3 weeks
of life until the child was 1 year of age. The intervention and control groups received a booklet and video
containing instructions on general skin care. Follow-up occurred at 1 year post intervention when the children in
the study were 2 years of age. There were no significant differences in incidence of AD at 2 years of age between
the intervention and control groups.
Skjerven et al. (2020) conducted a primary prevention multicenter, RCT with 2,397 infants. This study included
four groups, 1) the control group received usual care without specific skin care advice and recommendations to
follow national guidelines for infant nutrition; 2) the skin intervention group received baths with added
emollients followed by an application of face cream on at least 4 days per week; 3) the food intervention group
received early complementary feedings of peanut, cow's milk, wheat, and egg; and 4) the combined skin and
food group received the skin and food interventions. Interventions began at 2 weeks of life to 8 months of age.

Follow-up occurred at 12 months of life. The results of this study revealed no difference among the groups in the
prevention of AD.

Discussion and Recommendation
Small studies reported promising results that routine application of emollients starting within the first month of
life could prevent the development of AD in infants at high risk for this condition (Horimukai et al., 2014; Lowe,
Su, et al., 2018; McClanahan et al., 2019; Simpson et al., 2010; Simpson et al., 2014; Thitthiwong &
Koopitakkajorn, 2019). Results of these studies were limited by small sample sizes, short-term application of
emollients, and short-term follow-up. These limitations made level of evidence for these individual studies level
2 and the strength of these group of studies was B. Still, results of these earlier studies supported the need for
larger studies.
Two large studies with a combined sample size of 3,791 infants revealed no evidence that emollient use
prevents AD among infants at high risk (Chalmers et al., 2020; Skjerven et al., 2020). These studies tested
commonly used emollients and their protocols reflected practices that most families could accomplish without
onerous burden. Use of common skin-care products within these studies and less stringent application of the
emollients may have limited these results. Perhaps use of specially formulated emollient, applied beginning at
birth, more than once per day, and for an extended period may prevent AD (Chalmers et al.). However, though
potentially more effective, special emollients tend to be more expensive and not readily accessible, and most
families can not follow a stringent skin-care protocol for an extended period. Consistent findings from two highquality RCTs indicate that clinicians should not recommend use of emollients to prevent AD, the strength of this
recommendation is A (Ebell et al., 2004).

Clinical Implications: Advice for Parents
The skin of infants, regardless of risk for AD, is vulnerable to impaired integrity due to immaturity during the first
year of life. Although use of topical emollients will not prevent AD, they can still be recommended as part of
infant skin care to prevent dry skin and keep the infant comfortable. Clinicians should educate caregivers on
infant skin care and recommend suitable topical agents which do not adversely alter or affect the skin barrier
including bathe infants two to three times per week (Johnson & Hunt, 2019), clean infants' skin with water alone
or with a soap-free liquid cleanser formulated for infants, use soap-free cleansers, and apply emollients after
bathing (Blume-Peytavi et al., 2016; Tollefson et al., 2014). Soap-free cleansers include synthetic detergents or
syndets. Syndets are nonsoap surfactants that lower the surface tension in water to facilitate removal of dirt and
oils. Syndets have a neutral or slightly acidic pH, are less drying to skin, and cause less irritation. The most widely
used synthetic surfactants is sodium cocoyl isethionate, other syndets are sulfosuccinates, alpha
oleficategoriess, alkyl glyceryl ether sulfonate, sodium cocoyl monoglyceride, and sulfate and betaines.
Use of soaps on infants' skin should be avoided (Blume-Peytavi et al., 2016). Soaps have high pH often within the
range of 9 to 10, which is higher than the more alkaline pH of normal skin (Tarun et al., 2014). Soaps can
increase the pH of the skin causing dehydration of skin, irritation, itching, and alteration of normal bacterial
flora. Bar soaps and soap-based liquid cleansers can remove natural moisturizing factor and lipids from skin also
causing irritation, erythema, and itching. In soaps, surfactants remove sweat, sebum, deposits, and oil from the
skin, but they can also damage the stratum corneum leading to tightening of the skin, dryness, erythema,
irritation, and itch (Blume-Peytavi et al.).
Emollients may be applied after bathing when the infant's skin is still moist from the bath. White petroleum jelly
is an inexpensive emollient that does not contain contact allergens and is ideal for routine use of infants' skin
(Johnson & Hunt, 2019). Pharmaceutical-grade oils such as mineral oil are generally regarded as safe and can be

applied in a thin layer to the skin or added to the bath water. Caregivers need to be careful when applying
emollients and oils to ensure that they do not drop or cause the infant to fall because of the slipperiness.
Grocery oils, such as vegetable, olive, soybean, or mustard, are not recommended because they can leave film
or cause irritation that damages the skin (Chalmers et al., 2017). These oils can be degraded in hot, humid
environments or by cutaneous microbes present on the skin surface. Degraded oils become spoiled and support
increased microbial growth within the oil itself and on the skin (Telofski et al., 2012). Sunflower and olive oils
have been found to have an adverse effect by impeding the natural development of the intracellular lipids in the
stratum corneum which is significantly associated with reducing the skin barrier thus increasing the risk of AD
development (Cooke et al., 2016).
It is important for caregivers to read labels. Skin-care products may contain one or more common skin contact
allergens such as fragrances, betaines, methylchloroisothiazolinone, and lanolin. These ingredients should be
avoided as they may sensitize the infant and cause a Type IV hypersensitivity allergic contact dermatitis. Skincare products that contain sodium lauryl (laureth) sulfate should be avoided as this surfactant impairs the
integrity of the stratum corneum by making the lipids more water soluble, changing the molecular structure of
keratin, and raising the pH of the skin (Blume-Peytavi et al., 2016).

Conclusion
Although at first promising, the most current research does not support the use of topical emollients as a means
of preventing AD among infants. Clinicians may provide parents with evidence-based recommendations to care
for infants' skin.
BULLET LIST OF CLINICAL IMPLICATIONS
•
•
•
•
•
•

Recommend evidence-based skin care to prevent dry skin and increase infants' comfort.
Bathe infants two to three times per week with water alone or with a soap-free liquid cleanser
formulated for infants.
Avoid use of soaps on infants.
Apply emollients after bathing when skin is still moist.
White petroleum jelly or mineral oil are safe and effective moisturizers.
Avoid use of grocery oils, such as vegetable, olive, soybean, or mustard, on infants' skin.
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